Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder
This study has been completed.
Sponsor:
Boehringer Ingelheim Pharmaceuticals
Information provided by (Responsible Party):
Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00844194
First received: February 13, 2009
Last updated: May 18, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Results First Received: June 7, 2011
| Study Type: | Interventional |
|---|---|
| Study Design: | Allocation: Non-Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Open Label; Primary Purpose: Treatment |
| Conditions: |
Diabetic Neuropathies Depressive Disorder, Major |
| Interventions: |
Drug: Duloxetine 60 mg QD Drug: Duloxetine 30 mg QD Drug: Duloxetine 90 mg QD Drug: Duloxetine 120 mg QD |
Participant Flow
Recruitment Details
| Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations |
|---|
| No text entered. |
Pre-Assignment Details
| Significant events and approaches for the overall study following participant enrollment, but prior to group assignment |
|---|
| No text entered. |
Reporting Groups
| Description | |
|---|---|
| Without Major Depressive Disorder (MDD-) | Patients with diabetic polyneuropathy and no depression |
| With Major Depressive Disorder (MDD+) | Patients with diabetic polyneuropathy and depression |
Participant Flow: Overall Study
| Without Major Depressive Disorder (MDD-) | With Major Depressive Disorder (MDD+) | |
|---|---|---|
| STARTED | 78 | 30 |
| COMPLETED | 53 | 22 |
| NOT COMPLETED | 25 | 8 |
| Adverse Event | 17 | 5 |
| Protocol Violation | 1 | 1 |
| Lost to Follow-up | 1 | 1 |
| Withdrawal by Subject | 2 | 1 |
| Lack of Efficacy | 3 | 0 |
| Other reason (not specified) | 1 | 0 |
Baseline Characteristics
Reporting Groups
| Description | |
|---|---|
| Without Major Depressive Disorder (MDD-) | Patients with diabetic polyneuropathy and no depression |
| With Major Depressive Disorder (MDD+) | Patients with diabetic polyneuropathy and depression |
| Total | Total of all reporting groups |
Baseline Measures
| Without Major Depressive Disorder (MDD-) | With Major Depressive Disorder (MDD+) | Total | |
|---|---|---|---|
|
Number of Participants
[units: participants] |
78 | 30 | 108 |
|
Age
[units: Years] Mean ± Standard Deviation |
67.5 ± 10.2 | 66.6 ± 9.8 | 67.3 ± 10.1 |
|
Gender
[units: Participants] |
|||
| Female | 36 | 15 | 51 |
| Male | 42 | 15 | 57 |
Outcome Measures
| 1. Primary: | Change of Brief Pain Inventory (BPI) Average Interference Score From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 2. Primary: | Change of Brief Pain Inventory (BPI) Average Interference Score From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 3. Secondary: | Change of Brief Pain Inventory (BPI) Average Interference Score From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 4. Secondary: | Change in BPI Worst Pain During Treatment From Baseline to Week 2 [ Time Frame: Baseline and Week 2 ] |
| 5. Secondary: | Change in Worst Pain (BPI) From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 6. Secondary: | Change in Worst Pain (BPI) From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 7. Secondary: | Change in Least Pain (BPI) From Baseline to Week 2 [ Time Frame: Baseline and Week 2 ] |
| 8. Secondary: | Change in Least Pain During Treatment (BPI) From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 9. Secondary: | Change in Least Pain (BPI) From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 10. Secondary: | Change in Average Pain (BPI) From Baseline to Week 2 [ Time Frame: Baseline and Week 2 ] |
| 11. Secondary: | Change in Average Pain During Treatment (BPI) From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 12. Secondary: | Change in Average Pain (BPI) From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 13. Secondary: | Number of Patients With a Reduction in BPI Average Pain at Week 2 [ Time Frame: Baseline and Week 2 ] |
| 14. Secondary: | Number of Patients With a Reduction in BPI Average Pain at Week 6 [ Time Frame: Baseline and Week 6 ] |
| 15. Secondary: | Number of Patients With a Reduction in BPI Average Pain at Week 12 [ Time Frame: Baseline and Week 12 ] |
| 16. Secondary: | Change in Pain During Treatment (BPI) From Baseline to Week 2 [ Time Frame: Baseline and Week 2 ] |
| 17. Secondary: | Change in Pain (BPI) From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 18. Secondary: | Change in Pain During Treatment (BPI) From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 19. Secondary: | Change in Relief of Pain (BPI) From the Week Before Baseline to the Week Before Week 2 [ Time Frame: Baseline and Week 2 ] |
| 20. Secondary: | Change in Relief of Pain (BPI) From the Week Before Baseline to the Week Before Week 6 [ Time Frame: Baseline and Week 6 ] |
| 21. Secondary: | Change in Relief of Pain (BPI) From the Week Before Baseline to the Week Before Week 12 [ Time Frame: Baseline and Week 12 ] |
| 22. Secondary: | Change in Interference of Pain With General Activity (BPI) From Baseline to Week 2 [ Time Frame: Baseline and Week 2 ] |
| 23. Secondary: | Change in Interference of Pain With General Activity (BPI) From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 24. Secondary: | Change in Interference of Pain With General Activity (BPI) From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 25. Secondary: | Change in Interference of Pain With Mood (BPI) From Baseline to Week 2 [ Time Frame: Baseline and Week 2 ] |
| 26. Secondary: | Change in Interference of Pain With Mood (BPI) From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 27. Secondary: | Change in Interference of Pain With Mood (BPI) From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 28. Secondary: | Change in Interference of Pain With Walking Ability (BPI) From Baseline to Week 2 [ Time Frame: Baseline and Week 2 ] |
| 29. Secondary: | Change in Interference of Pain With Walking Ability (BPI) From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 30. Secondary: | Change in Interference of Pain With Walking Ability (BPI) From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 31. Secondary: | Change in Interference of Pain With Normal Work (BPI) From Baseline to Week 2 [ Time Frame: Baseline and Week 2 ] |
| 32. Secondary: | Change in Interference of Pain With Normal Work (BPI) From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 33. Secondary: | Change in Interference of Pain With Normal Work (BPI) From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 34. Secondary: | Change in Interference of Pain With Relations to Other People (BPI) From Baseline to Week 2 [ Time Frame: Baseline and Week 2 ] |
| 35. Secondary: | Change in Interference of Pain With Relations to Other People (BPI) From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 36. Secondary: | Change in Interference of Pain With Relations to Other People (BPI) From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 37. Secondary: | Change in Interference of Pain With Sleep (BPI) From Baseline to Week 2 [ Time Frame: Baseline and Week 2 ] |
| 38. Secondary: | Change in Interference of Pain With Sleep (BPI) From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 39. Secondary: | Change in Interference of Pain With Sleep (BPI) From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 40. Secondary: | Change in Interference of Pain With Enjoyment of Life (BPI) From Baseline to Week 2 [ Time Frame: Baseline and Week 2 ] |
| 41. Secondary: | Change in Interference of Pain With Enjoyment of Life (BPI) From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 42. Secondary: | Change in Interference of Pain With Enjoyment of Life (BPI) From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 43. Secondary: | Patient Global Impression - Improvement (PGI-I) at Week 2 [ Time Frame: Baseline and Week 2 ] |
| 44. Secondary: | Patient Global Impression - Improvement (PGI-I) at Week 6 [ Time Frame: Baseline and Week 6 ] |
| 45. Secondary: | Patient Global Impression - Improvement (PGI-I) at Week 12 [ Time Frame: Baseline and Week 12 ] |
| 46. Secondary: | Change in Beck Depression Inventory Total Score (BDI-II) From Baseline to Week 2 [ Time Frame: Baseline and Week 2 ] |
| 47. Secondary: | Change in Beck Depression Inventory Total Score (BDI-II) From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 48. Secondary: | Change in Beck Depression Inventory Total Score (BDI-II) From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 49. Secondary: | Change in Hospital Anxiety and Depression Scale (HADS) Anxiety Total Score From Baseline to Week 2 [ Time Frame: Baseline and Week 2 ] |
| 50. Secondary: | Change in HADS Anxiety Total Score From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 51. Secondary: | Change in HADS Anxiety Total Score From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 52. Secondary: | Change in HADS Depression Total Score From Baseline to Week 2 [ Time Frame: Baseline and Week 2 ] |
| 53. Secondary: | Change in HADS Depression Total Score From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 54. Secondary: | Change in HADS Depression Total Score From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 55. Secondary: | Change in Short Form Health Survey (SF-12) - Physical Component Summary From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 56. Secondary: | Change in Short Form Health Survey (SF-12) - Physical Component Summary From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 57. Secondary: | Change in Short Form Health Survey (SF-12) - Mental Component Summary From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 58. Secondary: | Change in Short Form Health Survey (SF-12) - Mental Component Summary From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 59. Secondary: | Change in Multidimensional Pain Inventory (MPI): Interference of Pain (With Subjective Well-being) From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 60. Secondary: | Change in Multidimensional Pain Inventory (MPI): Interference of Pain From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 61. Secondary: | Change in Multidimensional Pain Inventory (MPI): Support From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 62. Secondary: | Change in Multidimensional Pain Inventory (MPI): Support Which the Patient Received From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 63. Secondary: | Change in Multidimensional Pain Inventory (MPI): Pain Severity From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 64. Secondary: | Change in Multidimensional Pain Inventory (MPI): Pain Severity From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 65. Secondary: | Change in Multidimensional Pain Inventory (MPI): Life Control From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 66. Secondary: | Change in Multidimensional Pain Inventory (MPI): Life Control From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 67. Secondary: | Change in Multidimensional Pain Inventory (MPI): Affective Distress From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 68. Secondary: | Change in Multidimensional Pain Inventory (MPI): Affective Distress From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 69. Secondary: | Change in Multidimensional Pain Inventory (MPI): Negative Responses From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 70. Secondary: | Change in Multidimensional Pain Inventory (MPI): Negative Responses From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 71. Secondary: | Change in Multidimensional Pain Inventory (MPI): Solicitous Responses From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 72. Secondary: | Change in Multidimensional Pain Inventory (MPI): Solicitous Responses From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 73. Secondary: | Change in Multidimensional Pain Inventory (MPI): Degree to Which Significant Others Display Distracting Responses to the Patient's Pain Behaviors and Complaints From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 74. Secondary: | Change in Multidimensional Pain Inventory (MPI): Degree to Which Significant Others Display Distracting Responses to the Patient's Pain Behaviors and Complaints From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 75. Secondary: | Change in Multidimensional Pain Inventory (MPI): Household Chores From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 76. Secondary: | Change in Multidimensional Pain Inventory (MPI): Household Chores From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 77. Secondary: | Change in Multidimensional Pain Inventory (MPI): Outdoor Work From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 78. Secondary: | Change in Multidimensional Pain Inventory (MPI): Outdoor Work From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 79. Secondary: | Change in Multidimensional Pain Inventory (MPI): Social Activities From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 80. Secondary: | Change in Multidimensional Pain Inventory (MPI): Social Activities From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 81. Secondary: | Change in Multidimensional Pain Inventory (MPI): General Activities From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
Hide Outcome Measure 81| Measure Type | Secondary |
|---|---|
| Measure Title | Change in Multidimensional Pain Inventory (MPI): General Activities From Baseline to Week 6 |
| Measure Description | Frequency with which the patient engages in general activities. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently). |
| Time Frame | Baseline and Week 6 |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5 |
Reporting Groups
| Description | |
|---|---|
| Without Major Depressive Disorder (MDD-) | Patients with diabetic polyneuropathy and no depression |
| With Major Depressive Disorder (MDD+) | Patients with diabetic polyneuropathy and depression |
Measured Values
| Without Major Depressive Disorder (MDD-) | With Major Depressive Disorder (MDD+) | |
|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
71 | 30 |
|
Change in Multidimensional Pain Inventory (MPI): General Activities From Baseline to Week 6
[units: Scores on a scale] Mean ± Standard Deviation |
-0.2 ± 1.66 | 0.1 ± 0.60 |
No statistical analysis provided for Change in Multidimensional Pain Inventory (MPI): General Activities From Baseline to Week 6
| 82. Secondary: | Change in Multidimensional Pain Inventory (MPI): General Activities From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 83. Secondary: | Change in Clinical Global Impression - Severity Pain From Baseline to Week 2 [ Time Frame: Baseline and Week 2 ] |
| 84. Secondary: | Change in Clinical Global Impression - Severity Pain From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 85. Secondary: | Change in Clinical Global Impression - Severity Pain From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 86. Secondary: | Change in Hamilton Depression Score From Baseline to Week 2 [ Time Frame: Baseline and Week 2 ] |
| 87. Secondary: | Change in Hamilton Depression Score From Baseline to Week 6 [ Time Frame: Baseline and Week 6 ] |
| 88. Secondary: | Change in Hamilton Depression Score From Baseline to Week 12 [ Time Frame: Baseline and Week 12 ] |
| 89. Secondary: | Suicidal Thoughts by BDI-II at Week 2 [ Time Frame: Week 2 ] |
| 90. Secondary: | Suicidal Thoughts by BDI-II at Week 6 [ Time Frame: Week 6 ] |
| 91. Secondary: | Suicidal Thoughts by BDI-II at Week 12 [ Time Frame: Week 12 ] |
| 92. Secondary: | Suicidal Thoughts or Behaviours by HAMD-17 at Week 2 [ Time Frame: Week 2 ] |
| 93. Secondary: | Suicidal Thoughts or Behaviours by HAMD-17 at Week 6 [ Time Frame: Week 6 ] |
| 94. Secondary: | Suicidal Thoughts or Behaviours by HAMD-17 at Week 12 [ Time Frame: Week 12 ] |
| 95. Secondary: | Change of Fasting Blood Glucose From Baseline at Week 12 [ Time Frame: Baseline and Week 12 ] |
| 96. Secondary: | Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline at Week 12 [ Time Frame: Baseline and Week 12 ] |
| 97. Secondary: | Change of Systolic Blood Pressure From Baseline at Week 12 [ Time Frame: Baseline and Week 12 ] |
| 98. Secondary: | Change of Diastolic Blood Pressure From Baseline at Week 12 [ Time Frame: Baseline and Week 12 ] |
| 99. Secondary: | Change of Pulse Rate From Baseline at Week 12 [ Time Frame: Baseline and Week 12 ] |
More Information
Certain Agreements:
Limitations and Caveats
Results Point of Contact:
No publications provided
| Principal Investigators are NOT employed by the organization sponsoring the study. | ||||||
| There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. | ||||||
The agreement is:
|
Limitations and Caveats
| Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data |
|---|
| No text entered. |
Results Point of Contact:
Name/Title: Boehringer Ingelheim Call Center
Organization: Boehringer Ingelheim Pharmaceuticals
phone: 1-800-243-0127
e-mail: clintriage.rdg@boehringer-ingelheim.com
Organization: Boehringer Ingelheim Pharmaceuticals
phone: 1-800-243-0127
e-mail: clintriage.rdg@boehringer-ingelheim.com
No publications provided
| Responsible Party: | Boehringer Ingelheim Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00844194 History of Changes |
| Other Study ID Numbers: | 1208.34, 2008-002731-32 |
| Study First Received: | February 13, 2009 |
| Results First Received: | June 7, 2011 |
| Last Updated: | May 18, 2012 |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |